Scientists at the Veterinary Infectious Disease Organization (VIDO) in Saskatoon are researching immune responses to identify therapeutic targets for hantavirus.
The effort follows a recent outbreak on the cruise ship MV Hondius, where three people died [1, 2]. Because hantavirus can be fatal and lacks a standardized cure, identifying why some species resist the virus while humans do not is critical for developing life-saving medicine.
Researchers in Saskatchewan are specifically comparing how humans and deer mice react to the virus [1, 3]. Deer mice are primary carriers of the virus but do not suffer the same severe symptoms as humans. By analyzing these differing immune responses, VIDO scientists aim to find a biological pathway that can be targeted to stop the virus from causing systemic failure in people [1, 3].
This research has gained urgency as public concern grows over the MV Hondius fatalities [2]. The cruise ship outbreak has highlighted the vulnerability of travelers to zoonotic diseases, which are illnesses that jump from animals to humans.
While the VIDO lab focuses on immune-response targets, the outbreak has sparked misinformation on social media [4]. Some users have suggested ivermectin as a potential cure for hantavirus [4]. However, the scientific research being conducted in Saskatoon is focused on identifying specific therapeutic targets based on comparative immunology, not the use of antiparasitic drugs [1, 2].
The lab's work continues in Saskatoon, utilizing advanced modeling to understand the viral interaction with host cells [3]. This approach allows researchers to test how different proteins, and immune signals, contribute to the disease's progression in humans compared to the natural resilience found in the deer mouse.
“Three people have died in the hantavirus outbreak on the cruise ship MV Hondius.”
The focus on comparative immunology between humans and deer mice represents a strategic shift toward understanding host resilience rather than just attacking the virus itself. By identifying the specific mechanisms that allow deer mice to coexist with hantavirus without dying, researchers may find a way to mimic that protection in humans, potentially creating a first-of-its-kind targeted therapy for a disease that currently has a high mortality rate.
